Cerenome Launches CSF DNA/RNA Molecular Profiling Tests

Cerenome has launched its CNSide CSF Molecular Profile tests in the U.S. This expansion allows for the ordering of these diagnostics from Oct. 12, 2026, extending their application beyond leptomeningeal metastases to include primary central nervous system (CNS) tumors, CNS metastases, and hematologic CNS disease.